Press releases

At investor event Aktieportföljen Live, on October 15th, Chordate CEO Anders Weilandt talked about the appointment of Partner International Switzerland...
Chordate Medical Holding AB (publ) (”Chordate” or ”The Company”) announces the board’s resolution to appoint Partner International...
Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for market authorization for the migraine indication...
On Tuesday, October 15th, at 11:15, Chordate's CEO Anders Weilandt will participate at the investor event Aktieportföljen. He will present the...
Chordate Medical non-executive Director and main owner Caroline Lundgren Brandberg will participate in Feminvest's investor conference "Fearless"...
The American magazine Wired recently published an article on neuromodulation as an emerging method for treating migraines. Wired describes the technique...
Chordate Medical has received its first order for the Ozilia migraine treatment from Janin Medical, the company's distributor in Saudi Arabia. The...
Today, August 30th, Chordate's CEO Anders Weilandt presented the company's Q2 report for 2024 on Finwire TV. He also answered questions from...
At the annual general meeting in Chordate Medical Holding AB (publ) (“Chordate” or the "Company") held on 15 May 2024, it was resolved...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact